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Background. Chronic cyclosporine A (CsA)-induced nephropa-
thy is histologically characterized by tubular lesions, the intersti-
tial recruitment of inflammatory cells, arteriolopathy and focal
interstitial fibrosis. Recent studies show that the intrarenal inhi-
bition of matrix degradation and recruitment of monocytes/
macrophages into the kidney plays a critical role in the develop-
ment of renal interstitial fibrosis.
Methods. We examined the expression of components of the
matrix metalloproteinase (MMP) system and plasminogen activa-
tor inhibitor type-1 (PAI-1) in kidneys from rats injected daily s.c.
during three weeks with CsA (10, 15 or 20 mg CsA/kg body wt) or
vehicle solution.
Results. In all CsA-treated rats, serum creatinine levels were
significantly elevated compared to control levels. The extent of
CsA-induced atrophy was not influenced by the dosage during a
three-week CsA treatment. The administration of CsA did not
significantly increase total cortical interstitial collagen deposition,
whereas a-smooth muscle actin expression was significantly in-
creased in all CsA-treated rats. Analysis of the different subpopu-
lations of inflammatory cells recruited into the chronically injured
kidney revealed a marked influx of macrophages into fibrotic
cortical foci of CsA-treated rats. The number of cortical macro-
phages was highest in the group receiving the highest CsA dose.
PAI-1 antigen, present in proximal tubular lysosomes in kidneys
from all experimental groups, stained very intensely in atrophic
tubules in CsA-treated rats. Both stromelysin and interstitial
collagenase mRNA were expressed in the kidneys of control rats,
but their message transcription remained unaltered after CsA
treatment. In contrast, the expression of tissue inhibitor of matrix
metalloproteinase type 1 (TIMP-1) was significantly increased
after CsA treatment. TIMP-1 mRNA was undetectable in renal
sections from sodium-depleted vehicle-treated animals using the
in situ hybridization (ISH) technique. ISH of selected renal
sections of CsA-treated rats identified the cells responsible for the
increased TIMP-1 message transcription after CsA administra-
tion, mainly as interstitial cells and also as visceral and parietal
epithelial cells.
Conclusions. These results suggest that the locally increased
expression of TIMP-1 rather than a decrease of matrix metallo-
protease expression, contributes to the development of CsA-
induced focal interstitial fibrosis in the rat.
The long-term use of cyclosporine A (CsA) as an immu-
nosuppressant in several clinical settings is severely limited
by the occurrence of chronic nephropathy [1–4], which
consists of progressive renal failure, arterial hypertension
and proteinuria [4]. Histopathological changes in the kid-
ney comprise the recruitment of inflammatory cells [5],
obliterative arteriolopathy, tubular atrophy and interstitial
fibrosis [6]. These CsA-induced tubulointerstitial lesions
can readily be reproduced in rodents after three to six
weeks of CsA administration, provided a sodium-depletion
protocol is followed prior to or during CsA treatment
[7–13].
Investigation of the molecular events that lead to renal
fibrosis in different rodent models reveals three recurrent
themes: a marked infiltration of cells of the monocyte/
macrophage lineage, an up-regulated expression of the
fibrosis-promoting cytokine TGF-b1, and finally, distur-
bances in matrix turnover caused by increased fibrogenesis
and/or decreased fibrolysis [14]. One can perceive chronic
CsA-induced renal fibrosis as the result of uncontrolled
tissue repair in response to continuous low-dose toxic
insults. In response to CsA, activated and/or injured intrin-
sic renal cells release chemokines, cytokines and peptide
growth factors that recruit inflammatory cells into the
kidney, initiate the proliferation of fibroblasts and other
resident renal cells, and stimulate the release of several
factors that promote renal inflammation and interstitial
fibrosis. Furthermore, CsA reduces renal blood flow
through the release of vasoactive substances such as throm-
boxane and endothelin, and the resulting renal ischemia
promotes the synthesis of matrix proteins [15]. In addition,
CsA directly stimulates renal scarring by increasing colla-
gen production [16] and by increasing the synthesis of
transcription factors that promote TGF-b gene transcrip-
tion [17]. In normal tissue repair processes, immune cell
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and fibroblast activity are eventually repressed, cytokine/
chemoattractant release returns to baseline, the inflamma-
tory process is terminated, the provisional matrix is re-
solved and replaced by normal organ tissue. However,
repeated insults to the kidney triggered by long-term CsA
administration even in low doses can create a chronic,
vicious circle of cytokine and matrix overproduction that
ultimately leads to progressive interstitial fibrosis.
The interstitial matrix deposited in the scarred kidney is
produced by resident cells including activated fibroblasts,
recruited mononuclear cells and tubular epithelial cells
with a fibrogenic phenotype [18]. Renal matrix degradation
is largely regulated by two proteolytic systems that share
many features: the matrix metalloproteinase (MMP) sys-
tem and the plasminogen activating (PA) system. To date
16 vertebrate MMPs have been identified, which are loosely
classified into four groups according to protein sequence
and substrate specificity [19]. The first class includes inter-
stitial or fibroblast collagenase that hydrolyses all three
a-chains of native interstitial collagens, making them sus-
ceptible to degradation by gelatinases and other proteases
[20]. Secondly, the gelatinases are thought to play a role in
both basement membrane turnover (via collagen IV and V
breakdown) and in interstitial matrix turnover (via gela-
tinolytic activity) [20]. Thirdly, stromelysin-1 (or transin, as
it is called in the rat) is capable of degrading collagen types
II, IV, and V, gelatins, proteoglycans, fibronectin, casein
and laminin [20]. Finally, membrane-type MMPs that pos-
sess a transmembrane domain are involved in the activation
of proMMPs [19]. MMP-mediated matrix degradation is
inhibited by tissue inhibitor of matrix metalloproteinases
(TIMPs) of which four mammalian species have been
identified [21]. We studied the expression of TIMP-1,which
is produced by virtually all mesenchymal tissues including
intrinsic glomerular cells (mesangial cells and capillary
endothelium) and inflammatory cells such as macrophages
and fibroblasts [22]. The plasminogen activating (PA)
cascade can be blocked at the level of plasminogen activa-
tion by the PA inhibitor PAI-1, which results in the
inhibition of all subsequent plasmin-mediated activities
such as matrix degradation and proMMP activation [23]. In
several models of progressive renal fibrosis, matrix deposi-
tion highly exceeds the increases of matrix protein gene
transcription. This discrepancy results from decreased ma-
trix degradation, as in most models renal TIMP-1 [14] and
PAI-1 [14, 23] gene expression is up-regulated, while the
transcription of enzymes of the MMP and PA cascade
remains unaltered or decreases.
In the present study, we investigated the dose-dependent
effects of CsA on renal injury, on the recruitment of
inflammatory cells into the renal interstitium and on fibril-
lar collagen deposition. Until recently most attention in the
investigation of CsA-induced renal fibrosis has been fo-
cused on the expression of plasminogen activator inhibitor
type-1 (PAI-1) [13, 23]. This is the first report demonstrat-
ing that up-regulated TIMP-1 expression, rather than de-
creased MMP gene transcription, contributes to the devel-
opment of CsA-induced focal tubulointerstitial fibrosis in
the rat.
METHODS
Experimental set-up
The rat model of CsA-induced nephropathy used in this
study was previously described [12, 23]. Thirty male Wistar
rats, initial weight 200 g (Janssen Pharmaceuticals, Beerse,
Belgium), were randomly divided into four treatment
groups. During the entire study period, the rats were
housed in individual polypropylene cages under tempera-
ture-controlled conditions in a constant dark-light cycle.
CsA-treated animals were daily injected subcutaneously
(s.c.) with CsA (SandImmun® i.v.; Sandoz Pharmaceuticals
Company, Basel, Switzerland) during three weeks. Three
groups (N 5 8) were studied receiving following doses: 10,
15 and 20 mg CsA/kg body wt. The control group (N 5 6)
was s.c. injected daily with an amount of vehicle for CsA
(Cremophor® EL; Sandoz Pharmaceuticals Company), iso-
volumetric to the dose given to the 20 mg CsA/kg group.
Salt depletion, a necessary constituent of the model [11–13,
23], was induced by feeding the rats a sodium-deficient diet
based on AIN-76A (ICN Biomedicals, Brussels, Belgium)
during their exposure to CsA or vehicle-solution. In addi-
tion, renal sections from a separate experiment were used:
salt-depleted male Wistar rats were s.c. injected daily with
15 mg CsA/kg body wt or vehicle-solution for five weeks
and injected i.p. two hours before sacrifice with lipopoly-
saccharide (2 mg LPS/kg body wt; from E. coli, serotype
0128:B12; Sigma), which is known to increase plasma PAI-1
levels.
Sample collection
After three weeks of treatment, the rats were sacrificed
24 hours after receiving their last injection. The kidneys
were quickly prelevated, decapsulated and rinsed in sterile
saline solution. The right kidney was snap-frozen in liquid
nitrogen and stored at 280°C until RNA extraction was
performed. The left kidney was cut into 1 mm thick
transverse slices and processed for further histological
analysis using different fixation procedures. Serum samples
were taken at the time of sacrifice.
Serum creatinine and cyclosporine A levels
Serum creatinine levels were measured in duplicate using
a modified colorimetric Jaffe´ reaction (Creatinine Merck-
otest; Diagnostica Merck, Darmstadt, Germany). Serum
trough CsA levels were determined with a fluorescence
polarization immunoassay with a monoclonal antibody to
CsA (TDx/TDx FLx Cyclosporine Monoclonal Whole Blood
Assay; Abbott, Louvain-La-Neuve, Belgium).
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Cyclosporine A-induced morphological lesions
For light microscopy, rat kidney slices were fixed in
Dubosq-Brasil’s solution (an alcoholic based picroformol
fixative consisting of 0.77 g picric acid in an ethanol (400
ml):ddH2O (100 ml):neutral formol 40% (200 ml):acetic
acid (150 ml) mixture), embedded in paraffin, sectioned at
4 mm, and stained with periodic acid-Schiff (PAS) reagent.
Tubular injuries were analyzed as described earlier [23]. In
brief, the percentage of injured (atrophic, dilated, vacuol-
ized) tubules was counted in 2 mm2 of renal cortex.
Additionally, the extent of focal renal fibrosis was evaluated
by counting the number of fibrotic foci in the total cortex.
Methacarn (6:3:1 methanol/acetic acid/trichloroethane)-
fixed paraffin-embedded tissue was cut into 4 mm sections
and mounted on poly-L-lysine coated microscope slides
and rehydrated. After incubation with normal goat serum
[1/5 in Tris saline buffer (TSB: 10 mM Tris-HCl pH 7.6;
0.9% NaCl; 0.1% Triton X-100 and 0.004% merthiolate)]
during 20 minutes, rabbit anti-rat collagen I (1/3000 in
TSB), rabbit anti-rat collagen III (1/10000 in TSB) anti-
serum (Biogenesis Ltd., Bournemouth, UK) or murine
monoclonal anti-a smooth muscle actin directed to an
amino-terminal synthetic decapeptide of a-smooth muscle
actin (1/30000 in TSB; Sigma BioSciences) was applied and
incubated overnight. After washing in TSB, sections were
treated with biotinylated goat anti-rabbit antiserum or goat
anti-murine antiserum (1/200), followed by the addition of
the avidin-biotin peroxidase complex (Vector Laboratories
Inc., Burlingame, VT, USA). Color development was per-
formed with 3-amino-9-ethylcarbazole (AEC) as a chromo-
gen in the presence of H2O2. Interstitial collagen deposi-
tion and a-smooth muscle actin (a-SMA) stainings were
measured morphometically. In each renal section, stainings
were quantified in 20 randomly chosen cortical microscopic
fields at low magnification (2503, total surface area eval-
uated 1.7 mm2) by means of an image analyzer system
(Kontron Elektronik Imaging System KS400, release 2.0,
Germany). For the analysis of type I collagen and a-SMA,
only the interstitial expression was measured: the strongly
stained tunica media of arterioles and arteries were re-
jected manually from the measurement frames. The mea-
surements were expressed as fractional positive area [de-
fined as: (area above threshold divided by frame area) p
100]. Sections were evaluated without any knowledge of the
group affiliation of the individual rat.
Phenotyping of inflammatory cells
Macrophage stainings were performed on methacarn-
fixed, paraffin-embedded renal tissue with the ED1 mono-
clonal antibody (Serotec, Oxford, UK), directed to a cyto-
plasmic antigen of monocytes and tissue macrophages.
ED1 also recognizes dendritic cells [24]. Immunohisto-
chemical detection of lymphocytes was performed on 5 mm
renal tissue cryosections prefixed on melting ice during 90
minutes in 4% paraformaldehyde (BDH Chemical Ltd.,
Poole, UK) buffered with 0.1 M Na-cacodylate pH 7.4
containing 1% CaCl2. The W3/25 monoclonal antibody
(Serotec, Oxford, UK) used to detect T-helper cells is
directed to the rat CD4-equivalent, but also recognizes
macrophages [25]. The OX-8 monoclonal antibody (Sero-
tec) was used to detect T-suppressor/cytotoxic and natural
killer cells, and is directed to the rat CD8-equivalent [26]. B
lymphocytes were counted in sections stained with the
OX-4 monoclonal antibody (Harlan Sera-Lab Ltd., Sussex,
UK), which recognizes the Ia marker, present on B cells
and dendritic cells [27]. Polymorphonuclear neutrophils
were identified in hematoxylin eosin stained sections.
Infiltration was quantified as described for a previous
CsA nephropathy model [23]. In brief, cells showing dis-
tinct immunoreaction were counted in 28 randomly chosen
areas (magnification 3200; total surface area evaluated per
rat, 12 mm2) in the cortex. Thirty glomerular profiles per
renal section were examined for infiltrating cells. Inflam-
matory cells contained within large blood vessels or sur-
rounded by erythrocytes were excluded from all counts.
Results are expressed as absolute numbers of immunore-
active cells per mm2 or per glomerular cross section.
Sections were evaluated without knowledge of the group
affiliation of the individual rat.
Cellular proliferation
PAS sections immunostained for the proliferating cell
nuclear antigen (PCNA [28]) using the PC10 monoclonal
antibody (DAKO, Denmark) were used to evaluate cellular
proliferation and to localize proliferating cells. All PCNA-
positive nuclei within 16 randomly selected cortical micro-
scopic fields were counted (magnification 3200; cortical
area evaluated per rat, 7 mm2). Proliferation was examined
separately in intact tubules, in damaged tubules, in glomer-
uli and in the renal cortical interstitium. At least 40
glomerular cross sections were evaluated per rat. Results
were expressed as absolute numbers of PCNA-positive cells
per mm2 cortex or per glomerular cross section. Sections
were evaluated without knowledge of the group affiliation
of the individual rat.
Combined PCNA/ED1 immunohistochemical staining
To assess for intrarenal macrophage proliferation a
microwave-based two color immunohistochemical tech-
nique was used [29]. Methacarn-fixed paraffin-embedded
renal sections were labeled with ED1 and incubated with
biotinylated anti-mouse IgG, avidin and biotinylated alka-
line phophatase, after which chromogenic detection was
performed with nitroblue tetrazolium salt (NBT) and
5-bromo-4-chloro-3-indolyl phosphate (BCIP) in the pres-
ence of L-bromotetramisole. Before applying the second
monoclonal antibody, the primary and secondary antibody
from the first staining (ED1) were eliminated by microwave
heating (2 3 5 min) in 0.01 M Na-citrate pH 6.0. The second
Duymelinck et al: Inhibition of matrix degradation in the CsA-treated rat806
staining was performed using PC10, followed by incubation
in the presence of secondary biotinylated horse anti-mouse
immunoglobulins and avidin. Color development was
achieved with AEC in 0.01% H2O2.
Immunohistochemical staining for PAI-1
Renal tissue fixed on melting ice during 90 minutes in 4%
paraformaldehyde (BDH Chemical Ltd., Poole, UK) buf-
fered with 0.1 M Na-cacodylate pH 7.4 containing 1% CaCl2
and embedded in paraffin was sectioned at 4 mm, mounted
on poly-L-lysine coated slides, deparaffinized, rehydrated
and stained for PAI-1 as described earlier for a-SMA and
collagen. Unmasking of PAI-1 antigens was performed by
trypsin treatment and mouse anti-human PAI-1 monoclo-
nal antibody, MA-7F5 (provided by R. H. Lijnen and Dr. P.
Declerck, Center for Molecular and Vascular Biology,
Leuven, Belgium) [30] was applied for overnight incuba-
tion. Specificity of the primary antibody has been confirmed
in previous experiments [23]. To identify immunoreactive
PAI-1 cells, immunostaining was combined with PAS stain
and the chromogen 3,39-diaminobenzidene (DAB) was
used to visualize antigen-antibody staining.
Northern blot analysis
For Northern blot analysis, total RNA was isolated by
the guanidinium thiocyanate procedure [31]. The following
cDNA inserts were used as probes: 0.75 kb EcoRI cDNA
insert of pG4zTIMP for rabbit TIMP-1 [32] (a gift from Dr.
D. Edwards, University of West Ontario, Ontario, Canada),
0.8 kb cDNA insert of pCL-1 for rabbit collagenase and 1.2
kb cDNA insert of pSL-2 for rabbit stromelysin [33] (a gift
from Dr. Z. Werb, University of California, San Francisco,
CA, USA); the 0.3 kb PstI cDNA insert of pSPbact72,
containing part of the 39 untranslated region of b-actin (a
gift from Dr. U. Nudel, The Weizman Institute of Science,
Israel) [34]; the 1.3 kb cDNA insert of pRc GAP123 for rat
glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
[35] (a gift from Dr. R. Wu, Cornell University, Ithaca, NY,
USA). Total RNA (10 mg) was electrophoresed at 80V
through a denaturing 1.2% agarose gel containing 2.2 M
formaldehyde. The separated RNA was fixed on positively
charged nylon membranes (Hybond-N1 nylon membrane;
Amersham International Plc, Amersham, UK) by alkaline
vacuum transfer (Vacugene XL blotting unit; Pharmacia
LKB Biotechnology, Uppsala, Sweden). After amplification
of the plasmids containing the inserts, cDNA probes were
prepared according to standard procedures and 32P-labeled
by random primed DNA synthesis (Multiprime DNA label-
ing kit from Amersham International Plc, UK) to a specific
activity of approximately 0.5 to 1.109 cpm/mg DNA. After
overnight prehybridization at 42°C in hybridization solution
[53 standard saline citrate (SSC); 0.1% (wt/vol) SDS; 53
Denhardt’s solution; 50 mM sodium phosphate pH 7.0; 0.25
mg/ml denaturated sonicated salmon sperm DNA and 50%
deionized formamide], the labeled probe was added to
hybridize for 24 hours under the same conditions. Strin-
gency of the washes for each probe was determined in
preliminary experiments. Finally, blots were exposed to
preflashed Fuji HRG autoradiographic film (Fuji, Japan) at
280°C in a film cassette with two intensifying screens. For
quantification, hybridization signals of the blots were
scanned densitometrically and integrated by a digital imag-
ing system (Datacopy GS1 scanner, Imagecopy 1.10 soft-
ware; Xerox, USA) and image analyzer system (Kontron
Elektronik Imaging System KS400, release 2.0, Germany).
Variations in isolation, application, or transfer of total
RNA were accounted for by reprobing the blots with a
cDNA probe for GAPDH or b-actin.
The transcription of the housekeeping genes GAPDH
and b-actin was investigated in kidneys of experimental
rats. A mild but significant increase of b-actin mRNA was
observed in CsA-treated rats. Since the expression of
GAPDH mRNA was constant after CsA treatment with
different doses, all mRNA concentrations were expressed
in relation to GAPDH mRNA levels.
Riboprobe preparation for in situ hybridization
The plasmid pBSTIMP1 containing full length rat
TIMP-1 cDNA (750 bp) inserted into the pBluescript II
SK1 phagemid was provided by Dr. A. Okada (Inserm,
Illkirch Cedex, France) [36]. The plasmid construct was
linearized using the appropriate restriction enzymes
(HindIII for the TIMP-1 antisense riboprobes and BamHI
for the sense TIMP-1 RNA probe) and transcribed using
bacteriophage RNA polymerases (T3 RNA polymerase for
TIMP-1 antisense and T7 RNA polymerase for TIMP-1
sense probe) in the presence of fluorescein-11-UTP to
generate fluorescein-labeled antisense and sense ribo-
probes according to the manufacturer’s instructions (RNA
color kit; Amersham). Riboprobe integrity and molecular
weight were checked on a 0.8% agarose gel and an estima-
tion of RNA probe concentration was made using UV
absorption spectrophotometry.
In situ hybridization
For in situ hybridization (ISH), selected Dubosq-Brasil’s
fixed paraffin-embedded sections were dewaxed in toluene,
rehydrated through decreasing graded ethanol, rinsed in
diethylpyrocarbonate (DEPC)-treated saline and PBS and
fixed for 20 minutes in 4% paraformaldehyde at 4°C. After
rinsing in DEPC-PBS, the tissue was permeabilized in 5
mg/ml nuclease-free proteinase K (Boehringer Mannheim)
for 20 minutes at 37°C, rinsed in DEPC-PBS and post-fixed
in 4% paraformaldehyde at 4°C for 20 minutes. After
dehydration in increasing graded ethanols, 25 ml hybridiza-
tion solution (45% deionized formamide, 13 Denhardt’s
solution, 0.017 M Tris, 9% dextran sulfate, 4.4 mM EDTA,
0.3 M NaCl, 0.5 mg/ml yeast tRNA, 1 mM dithiotreithol)
containing fluorescein-labeled RNA probe was added to
each slide. Sections were covered with a coverslip and
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incubated overnight in a humidified box at 55°C. After
hybridization, the coverslips were removed in 5 3 SSC and
sections were incubated for 30 minutes in 50% deionized
formamide and 2 3 SSC at 65°C to inhibit endogenous
alkaline phosphatase activity and to remove nonspecifically
bound probe. Sections were rinsed in saline Tris-EDTA
buffer (NTE) and background was reduced by incubating in
20 mg/ml ribonuclease A (Boehringer Mannheim) for 35
minutes at 37°C. After rinsing in NTE, sections were
incubated at 65°C in 50% deionized formamide in 2 3 SSC
for 30 minutes, and washed for 15 minutes in 2 3 SSC at
50°C and for 15 minutes in 0.1 3 SSC at 50°C. Hybridized
probes were detected according to the manufacturer’s
instructions using the RNA color kit (Amersham). In short,
the detection required an anti-fluorescein antibody conju-
gated to alkaline phosphatase and a color-substrate solu-
tion consisting of NBT and BCIP. After immunostaining,
sections were stained with periodic acid-Schiff reagent,
counterstained with methyl green and mounted in glycerol/
gelatin. To check the specificity of the fluorescein-labeled
antisense riboprobes, in each hybridization run, sections
were hybridized with the fluorescein-labeled sense RNA
probe or incubated in hybridization solution without probe.
Statistical methods
All data are represented as mean 6 SD. Differences
between groups were investigated with ANOVA followed
by group-to-group comparisons with the post-hoc Student-
Newman-Keuls test. Non-parametric variables were ana-
lyzed with the Kruskal-Wallis ANOVA and Mann-Whitney
U-test. In all circumstances, P , 0.05 was considered to
be significant. Statistical analysis was computed using
STATISTICA (release 4.3) for MicroSoft Windows.
RESULTS
Functional parameters
There was no mortality during the course of the study. At
the start of the treatment, the mean body wt was 242 6
12 g. At the time of sacrifice, mean body wt in the
vehicle-treated group was significantly higher than in the
cyclosporine-treated groups (Table 1). The higher the CsA
dose, the smaller the weight gain of the animals after three
weeks of CsA treatment. Serum creatinine values were
significantly increased in all CsA-treated groups compared
to the vehicle-treated group (Table 1). There was no
difference between the serum creatinine levels of the
CsA-dosage groups. CsA serum trough levels were signifi-
cantly lower in the group that received 10 mg CsA/kg body
wt compared to the CsA-treated groups receiving a higher
dose (Table 1).
Renal morphology
In our experimental set-up, CsA caused mild focal
tubulointerstitial lesions consisting of tubular atrophy,
proximal tubular cell vacuolization and the formation of
foci of atrophic tubules in inflamed fibrotic cortical tissue
(Table 2). In a few of the CsA-treated animals, a portion of
the lesions displayed a characteristic striped distribution
extending perpendicularly from the cortico-medullary junc-
tion. Examination of the total cortex (Table 2) showed that
despite a tendency towards an aggravation of CsA-induced
tubular lesions after raising the CsA dosage, only the
number of tubules with vacuolized epithelium was signifi-
cantly increased in the group receiving the highest dose.
Isovolumetric vacuolization, a nonspecific but highly char-
acteristic lesion of CsA-induced nephropathy, is a dose-
dependent tubulotoxic effect, as is clearly demonstrated by
our results.
In control rats, collagen I protein was expressed in the
tunica media of arteries and arterioles, but collagen I was
also deposited to a limited extent in the cortical intersti-
tium. Increasing CsA dosage increased type I collagen
immunostaining in zones containing atrophic tubules. How-
ever, morphometric analysis of randomly chosen cortical
areas revealed no significant increase of collagen type I
deposition after CsA treatment (Table 2). The deposition
of collagen type III in the adventitia of blood vessels,
surrounding glomeruli and tubules in the cortex of control
rat kidneys, tended to increase when the rats were treated
with high CsA doses, but the increase of collagen III
immunostaining did not reach a significant level when
Table 1. Functional parameters
CsA dose mg/kg body wt P
value0 10 15 20
Body weight (g) at time of sacrifice 345 6 11a 313 6 24b 271 6 25 266 6 19 0.0000
Serum creatinine mg/dl 0.41 6 0.05a 0.64 6 0.15 0.66 6 0.14 0.62 6 0.12 0.0038
CsA serum trough levels ng/ml 0 6 0a 1761 6 373b 3009 6 846 3725 6 1096 0.0001
Results are expressed as mean 6 SD. Body weight and serum creatinine levels were analyzed with ANOVA followed by group-to-group comparisons
with the post-hoc Student-Newman-Keuls test.
CsA serum trough levels were analyzed with the Kruskal-Wallis ANOVA and Mann-Whitney U test.
a P , 0.05, significantly different from all three CsA-treated groups
b P , 0.05, significantly different from the groups receiving a higher CsA dose
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random cortical areas were measured morphometically,
due to the focal nature of CsA-induced interstitial fibrosis
(Table 2).
In normal rats a-SMA was constitutively expressed by
vascular smooth muscle cells in cortical arteries and arte-
rioles. In salt-depleted vehicle-treated animals sparse
a-SMA positive interstitial cells were found around Bow-
man’s capsule and in the interstitial space between tubules
(Fig. 1A). In renal sections of CsA-treated rats, foci of
a-SMA immunostained cells were detected in the peritu-
bular area (Fig. 1B) and around Bowman’s capsule in the
cortex. The fractional cortical area positive for a-SMA was
significantly increased in all CsA-treated rats (Table 2).
Phenotyping of inflammatory cells
Kidneys from vehicle-treated rats contained very few
ED1 positive cells (Fig. 2A and Table 3). The number of
interstitial ED1 expressing cells in the total cortex was
significantly increased after CsA treatment and the highest
number of macrophages was found in the group receiving
the highest dose (Table 3). In CsA-treated rats macro-
phages were located in subcapsular fibrotic foci and were
sparse in adjacent intact areas (Fig. 2B). CsA also signifi-
cantly increased the number of ED1 immunoreactive cells
within the glomerular tuft (Table 3). The higher number of
macrophages was not only due to an increased renal influx
in response to CsA, but was also due to proliferation, as
some of the interstitial cells were stained for both ED1 and
PCNA (Fig. 2C). The W3/25 positive inflammatory cells (T
helper cells and macrophages) were abundantly present in
kidneys from all rats and were associated with fibrotic foci
in CsA-treated rats (although not to the same extent as
ED1 positive cells), but their numbers were not increased
in the CsA-treated groups compared with the vehicle-
treated group. The W3/25 monoclonal antibody, directed to
the rat CD4-equivalent, not only recognizes T helper cells
Table 2. Renal histopathological changes after 3 weeks of CsA treatment
CsA dose mg/kg body wt P
value0 10 15 20
Histological lesions
Tubular atrophy 0.2 6 0.2a 20.7 6 10.7 20.2 6 11.2 28.3 6 4.9 0.0026
Tubular vacuolization 0.9 6 1.2a 7.8 6 3.9 10.3 6 4.7 15.7 6 3.7b 0.0000
Tubular dilatation 0.8 6 1.0 3.2 6 2.6 3.6 6 2.8 4.2 6 2.1 0.0829
Number of cortical fibrotic foci 0 6 0a 49.0 6 28.5 41.5 6 16.9 57.5 6 19.1 0.0026
Immunohistochemistry
Fractional positive area for collagen type I 0.94 6 0.77 1.23 6 0.21 2.37 6 2.22 2.00 6 1.13 0.2483
Fractional positive area for collagen type III 2.31 6 1.45 2.42 6 0.91 4.12 6 1.43 3.87 6 0.56 0.1405
Fractional positive area for a-SMA 0.08 6 0.04a 0.19 6 0.09 0.19 6 0.14 0.27 6 0.12 0.0038
Histological lesions are expressed as percentage of injured tubules (mean 6 SD). Tubular atrophy, number of fibrotic foci and collagen I and a-SMA
were analyzed with the Kruskal-Wallis ANOVA and Mann-Whitney U test. All other data were tested with ANOVA followed by group-to-group
comparisons with the post-hoc Student-Newman-Keuls test.
a P , 0.05, significantly different from all CsA-treated groups
b P , 0.05, significantly different from CsA-treated groups receiving a lower dose
Table 3. Phenotyping of inflammatory cells
CsA dose mg/kg body wt
0 10 15 20
Interstitial infiltration
ED1 positive cells 23.5 6 10.3a 179.2 6 52.4 150.1 6 84.9 252.0 6 35.0
W3/25 positive cells 113.4 6 70.1 51.3 6 61.0 150.6 6 67.4 64.8 6 31.0
OX-4 positive cells 77.3 6 46.1 123.6 6 115.6 116.6 6 74.5 158.1 6 115.8
OX-8 positive cells 38.7 6 17.1 26.1 6 15.9 32.2 6 6.9 36.8 6 14.3
Neutrophils 4.4 6 3.8b 9.6 6 4.0 11.9 6 3.9 8.2 6 5.4
Inflammatory cells per glomerular
cross section
ED1 positive cells 0.76 6 0.24a 2.70 6 0.51 2.89 6 1.04 2.75 6 0.72
W3/25 positive cells 0.25 6 0.30 0.12 6 0.15 0.37 6 0.16 0.12 6 0.08b
OX-4 positive cells 0.32 6 0.31 0.20 6 0.08 0.36 6 0.41 0.19 6 0.14
OX-8 positive cells 0.12 6 0.07 0.13 6 0.05 0.19 6 0.08 0.06 6 0.03b
Neutrophils 0.10 6 0.05 0.15 6 0.15 0.21 6 0.07c 0.38 6 0.25c
Results are expressed as number of immunoreactive cells per mm2 cortical surface area or per glomerular cross section (mean 6 SD). The number
of OX-8 positive cells in interstitium and in glomerular cross sections and glomerular ED1 were analyzed with ANOVA followed by group-to-group
comparisons with the post-hoc Student-Newman-Keuls test, while all other data were tested with the Kruskal-Wallis ANOVA and Mann-Whitney U
test.
a P , 0.05 significantly different from all CsA-treated groups
b P , 0.05 significantly different from the group treated with 15 mg CsA/kg body wt
c P , 0.05 significantly different from controls and from the group receiving 10 mg CsA/kg body wt
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but also macrophages, and probably another interstitial cell
type that remains to be identified, which explains the
relatively high number of W3/25 immunoreactive cells
counted in control rats. In all renal sections B lymphocytes
were present in the vicinity of blood vessels, but their
recruitment into the kidney was not stimulated by CsA.
Cytotoxic T cells and neutrophils were sparse in all exper-
imental groups.
Cellular proliferation
The number of proliferating cells in control rats was
negligible (Fig. 2A). PCNA positivity was most pronounced
in the interstitial compartment and in injured tubules (that
is, atrophic tubules, tubules with a dilated lumen or vacu-
olized epithelial cells) in scarred cortical foci of CsA-
treated rats, whereas it was almost absent in adjacent intact
areas (Fig. 2). Analysis of randomly chosen cortical fields
showed that only the rats receiving 20 mg CsA/kg body wt
had significantly higher numbers of PCNA immunoreactive
cells in injured tubules, in the cortical interstitium and
glomeruli compared to rats receiving vehicle solution (Fig.
3). The lack of significantly increased numbers of PCNA
positive nuclei in both groups receiving lower doses is due
to the focal nature of the CsA-induced lesions.
Immunohistochemical staining for PAI-1
PAI-1 antigen was immunodetectable in kidneys from all
experimental groups. In vehicle-treated salt-depleted rats,
Fig. 3. Quantification of cellular proliferation in the cortex. Proliferation was quantified separately in damaged tubules (atrophy, dilation,
vacuolization; A), in intact tubules (B), in the cortical interstitium (C) and in glomeruli. Results are expressed as number of PCNA positive nuclei per
mm2 cortex. Symbols are: ( ) mean; (F) individual measurement. *P , 0.05. PCNA positivity was much less pronounced in the glomerular
compartment: per glomerulus 0.6 6 0.2; 0.6 6 0.2; 1.1 6 0.5 and 2.5 6 2.0 PCNA positive nuclei were counted in the vehicle-treated, 10, 15 and 20 mg
CsA/kg body wt groups, respectively. All data, except PCNA positivity in healthy tubules, were analyzed with ANOVA followed by post-hoc
Student-Newman-Keuls testing.
Fig. 1 (upper panels). Immunohistochemical a-smooth muscle actin (a-SMA) staining. (A) In the salt-depleted vehicle-treated rat very few interstitial
cells are a-SMA positive. (B) After CsA treatment (20 mg CsA/kg body wt, 3 weeks) foci of a-SMA expressing interstitial cells are located peritubularly
in the subcapsular and deeper cortex. Magnification 3422. The publication of this figure in color was made possible, in part, by a grant from Novartis
Pharma Belgium.
Fig. 2 (middle panels). Combined PCNA/ED1 immunohistochemical staining. A microwave-based dual-labeling immunohistochemical technique was
used to stain for both proliferating cells (PCNA, brown nuclear staining) and macrophages (ED1, black cytoplasmic staining). (A) In kidneys of control
rats a limited number of PCNA positive nuclei were found in tubules and in the interstitium. Macrophages were absent. (B) In CsA-treated rats (20
mg CsA/kg body wt, 3 weeks) PCNA positive nuclei were associated with focal damaged areas, while adjacent intact areas contained few proliferating
cells. Macrophages were even more evidently associated with fibrotic foci. (C) Detail of panel B. Cellular proliferation is pronounced in injured
(vacuolized, dilated and atrophic) tubules and in the interstitium. Macrophages surround atrophic tubules and infiltrate the glomerular tuft. The
increased number of macrophages in CsA-treated rats is not only due to infiltration but also due to proliferation as a subpopulation of macrophages
is PCNA positive (arrows). Magnification for A and B 3105; for C, 3422. The publication of this figure in color was made possible, in part, by a grant
from Novartis Pharma Belgium.
Fig. 4 (lower panels). Immunohistochemical PAI-1 staining. (A) In vehicle-treated sodium-depleted rats, PAI-1 was mainly found in small vesicles
(lysosomes) in proximal tubular cells and in visceral epithelium of glomeruli. (B) In renal sections of CsA-treated rats (15 mg CsA/kg body wt, 3 weeks)
enlarged PAI-1 positive vesicles were observed in atrophic tubules (arrows). Magnification 3338. The publication of this figure in color was made
possible, in part, by a grant from Novartis Pharma Belgium.
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PAI-1 immunoreactive vesicles (lysosomes) were observed
in proximal tubular cells (Fig. 4A), mainly in the S1S2
portion of the proximal tubule, and PAI-1 was also found as
cytoplasmic staining of arterial smooth muscle and visceral
epithelial cells. In addition to these signals in control kidneys,
larger and more intensely stained PAI-1 vesicles were present
Fig. 5. Northern blot and densitometric
analysis of whole kidney RNA for interstitial
collagenase (A) and stromelysin (B) expression.
The injected CsA dose is shown under the
densitometry graphs. The autoradiograph of
GAPDH shows the amount of RNA loaded.
Densitometric analyses of the autoradiographs
corrected for any RNA loading errors are
represented in the bar graphs. Results are
expressed as mean 6 SD. Data were analyzed
with the Kruskal-Wallis ANOVA.
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in atrophic proximal tubules in damaged cortical foci (arrows,
Fig. 4B) in kidneys of rats receiving CsA. PAI-1 immunostain-
ing was comparable in all CsA-treated groups.
Matrix metalloproteinase expression
The rabbit collagenase cDNA probe identified an intense
band in control renal rat tissue (Fig. 5A). Low levels of
stromelysin transcripts were detected in the kidneys of
control rats (Fig. 5B). Normalization for differences in
mRNA loading revealed no significant difference between
the renal mRNA levels for interstitial collagenase (P 5
0.2165) and stromelysin (P 5 0.3611) of the four experi-
mental groups (Fig. 5).
TIMP-1 expression
Only trace amounts of TIMP-1 mRNA could be detected
in control kidneys (Fig. 6), but TIMP-1 expression was
significantly increased (P , 0.0329) in renal tissue from all
CsA-treated rats (Fig. 6). The highest TIMP-1/GAPDH
ratios were measured in renal RNA extracts derived from
rats receiving the highest CsA-dose. A significant linear
correlation (R 5 0.833; P , 0.001) was found between the
CsA dose and TIMP-1 mRNA expression.
In situ hybridization (ISH) with the hybridization solu-
tion lacking an RNA probe, proved that endogenous
alkaline phosphatase activity was completely inhibited after
the high temperature washes applied in the ISH protocol
(data not shown). In sections of animals fed a sodium-
deficient diet and treated with vehicle-solution (for 3 or 5
weeks) no TIMP-1 transcribing cells were detected (Fig.
7A). Hybridization of selected sections (of animals treated
for 5 weeks with CsA and injected i.p. with LPS 2 hr before
sacrifice) with the antisense TIMP-1 RNA probe gave
abundant signals in interstitial cells (Fig. 7 B, D). TIMP-1
mRNA transcribing interstitial cells were mainly located in
injured areas in peritubular and periglomerular positions,
or between inflammatory cells and fibroblasts in the wid-
ened interstitial space (Fig. 7 B, D). Parietal and visceral
epithelial cells also expressed TIMP-1 message (Fig. 7F)
and glomeruli expressing TIMP-1 were located in the
injured cortex (Fig. 7B). Some smooth muscle cells of
arterioles and arteries were positive for TIMP-1 mRNA. In
intact areas TIMP-1 transcribing cells (interstitial or glo-
merular) were sparse or absent (Fig. 7E). Negative controls
to assess aspecific probe adhesion to renal tissue were
performed with the TIMP-1 sense riboprobe and gave no
signals (Fig. 7C). In sections of control animals receiving a
single i.p. injection with LPS two hours before sacrifice, no
TIMP-1 mRNA signals could be detected with the ISH
technique (data not shown).
DISCUSSION
We examined the dose-dependent effects of CsA on the
expression of fibrosis-related proteins in a model of chronic
Fig. 6. Northern blot and densitometric
analysis of whole kidney RNA for tissue
inhibitor of matrix metalloproteinases (TIMP-
1) expression. The injected CsA dose is shown
under the densitometry graphs. The
autoradiograph of GAPDH shows the amount
of RNA loaded. Densitometric analysis of the
autoradiograph corrected for any RNA loading
errors is represented in the bar graphs. Results
are expressed as mean 6 SD. Data were
analyzed with the Kruskal-Wallis ANOVA, and
group-to-group comparisons were made with
the Mann-Whitney U-test (*P , 0.05;
significantly different from the CsA-treated
groups).
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CsA-induced nephropathy with focal fibrotic lesions, rele-
vant for the study of human CsA-induced renal tubuloin-
terstitial disease. Fibrosis results from increased ECM
production and decreased ECM degradation due to de-
creased protease synthesis and/or increased protease inhib-
itor expression. In this report we demonstrate that after
three weeks of sodium-depletion and CsA administration,
the expression of the metalloproteases, interstitial collage-
nase and stromelysin-1, remained at baseline, while their
inhibitor TIMP-1 was overexpressed, adding CsA nephrop-
athy to the growing list of fibrotic nephropathies in which
disturbances in the metalloproteinase system are an impor-
tant feature.
TIMP-1 is a glycoprotein that is produced by virtually all
mesenchymal tissues including glomerular cells and inflam-
matory cells such as macrophages and fibroblasts [22].
TIMP-1 mRNA expressing cells were not detected in
kidneys from sodium-depleted rats treated for three or five
weeks with vehicle-solution. After five weeks of CsA ad-
ministration and sodium depletion (and a single LPS
injection), TIMP-1 mRNA was transcribed by visceral and
parietal epithelium, but most TIMP-1 expressing cells were
interstitial. TIMP-1 mRNA positive interstitial and glomer-
ular cells were confined to injured areas. The interstitial
cortical cells expressing TIMP-1 message could be resident
macrophages or macrophages recruited into the injured
areas, fibroblasts and/or resident renal cells that acquired
fibrogenic mesenchymal cell characteristics as foci of
a-SMA expressing cells were found in the cortex after CsA
treatment. In rats injected with a single dose of LPS two
hours before sacrifice, no renal TIMP-1 transcribing cells
were detected. This may be due to the relative slow on/off
transcription kinetics of TIMP-1 [37], but does not exclude
an additive stimulatory effect of LPS on TIMP-1 gene
expression in CsA-treated rats because in vitro, LPS stim-
ulates TIMP-1 synthesis by both monocyte-derived macro-
phages and their in vivo differentiated counterparts [38,
39]. Little is known about the effect of CsA on TIMP-1
expression. The in vitro effects of CsA on TIMP-1 expres-
sion by human gingival fibroblast strains displays both
inter-individual and intra-individual (different strains de-
rived from one individual) heterogeneity [40], and in
human dermal fibroblast cultures CsA does not affect
TIMP-1 expression [41]. Increased TIMP-1 expression pre-
cedes and coincides with fibrogenesis in several rodent
renal fibrosis models, but most studies lack information on
MMP expression and the identification of the TIMP-1
transcribing cells. In acute puromycin aminonucleoside
(PAN) nephrosis, stromelysin expression remains at con-
trol values, while TIMP-1 mRNA levels are transiently
increased 5-fold at week 1 and collagenase expression
increases two- to threefold at weeks 2 and 3 [42, 43]. After
sustained injury induced by repeated PAN injections,
stromelysin and collagenase expression remain unaltered
while TIMP-1 message levels increase for several weeks,
and interstitial TIMP-1 immunostaining increases and per-
sists as the interstitial space widens [44]. Focal segmental
TIMP deposits appear in glomeruli at a later stage of the
disease [44]. Hypercholesteremic uninephrectomized rats
develop interstitial fibrosis after 12 weeks, preceded by
increased renal TIMP-1 mRNA transcription and the de
novo interstitial appearance of TIMP-1 protein [45]. In the
former two studies, TIMP-1 antigen was stained with rabbit
anti-bovine TIMP-1 antiserum [46], which we suspect re-
acts aspecifically in the rat kidney, since preabsorption of
this antiserum to purified bovine TIMP-1 or recombinant
human TIMP-1 does not obliterate positive signals, irre-
spective of the detection method (chromogenic or indirect
immunofluorescence) and tissue preparation (unfixed cry-
ostat sections or fixed paraffin-embedded tissue). After
unilateral ureteral obstruction of the rat, interstitial fibrosis
develops that often evolves to end-stage renal disease.
Twelve hours after ureteral ligation TIMP-1 message levels
in the obstructed kidney start to rise compared to the levels
found in the unobstructed contralateral kidney or kidneys
from sham-operated rats [47]. In protein-overload protein-
uria induced in uninephrectomized rats by daily bovine
serum albumin injections, stromelysin levels remain unal-
tered during the first three weeks [22]. TIMP-1 mRNA
levels are significantly elevated one week after the onset of
proteinuria and although interstitial cells are the main site
of TIMP gene transcription, some tubular cells contain
TIMP-1 message [22]. In the model of passive Heymann
nephritis, a transient increase of TIMP-1 gene expression
between days 7 and 9 precedes the development of focal
interstitial fibrosis [14]. In summary, in several rodent
fibrosis models increased TIMP expression appears to be
an early event in fibrogenic processes that appears persis-
tent when the renal insult is sustained.
Distinct from its protease inhibitory actions, TIMP-1
Fig. 7. In situ hybridization (ISH) for TIMP-1 mRNA (A, B, D, E, F) and control hybridization to verify the specificity of the signal (C). (A) ISH of
kidneys of vehicle-treated salt-depleted rats (3 weeks) with the TIMP-1 antisense probe revealed no TIMP-1 transcribing cells. (B) ISH with the
antisense TIMP-1 probe of renal sections from CsA-treated rats (15 mg CsA/kg body wt, 5 weeks) shows that interstitial cells in damaged areas are the
main site of TIMP-1 gene transcription. TIMP-1 mRNA is also expressed by glomerular cells. (D; detail of B) TIMP-1 expressing interstitial cells were
mainly present in injured areas in the vicinity of damaged tubules or in the widened interstitial space (arrow). (E; detail of B) In adjacent intact areas,
TIMP-1 transcribing interstitial and glomerular cells were sparse or absent. (F) Glomerular TIMP expressing cells included epithelial cells of Bowman’s
capsule (black arrow) and visceral epithelial cells (open arrow). (C) In each hybridization, consecutive sections were hybridized with sense TIMP-1
riboprobe to assess for aspecific probe adhesion to renal tissue. ISH signals were not observed in any of the negative controls. Magnification A-C, 3105;
D, E, 3422; F, 3675. The publication of this figure in color was made possible, in part, by a grant from Novartis Pharma, Belgium.
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displays in vitro growth factor activities on epithelial cells
and fibroblasts [48, 49]. Specific binding of TIMP-1 to cells
sensitive to its growth potentiating effects suggests that
these effects are receptor-mediated [48]. A TIMP-induced
stimulation of fibroblast proliferation may have significant
implications on the matrix-producing potential of the fibro-
genic kidney, especially since TIMP-induced growth stim-
ulation of epithelial cells and fibroblasts occurs in the
nanomolar range [48]. As other bifunctional molecules
such as plasmin, plasminogen activators and the trypsin
inhibitor share this growth stimulating activity, there may
be an evolutionary link between growth stimulation and
regulation of proteolytic activity that has diverged but is
still combined in certain proteins [48]. The in vivo relevance
of the growth factor activities of TIMPs remains to be
demonstrated, but in the rat model of chronic CsA ne-
phropathy, tubular and interstitial cell proliferation pre-
cedes and coincides with the development of interstitial
fibrosis [50], while TIMP-1 expression also appears to be an
early event. Further evidence suggesting a possible link
between fibrosis and proliferation was put forward by Kuze
et al, who demonstrated the increased production of a
protein in the remnant kidney that binds to the bidirec-
tional promoter of two collagen IV chains genes and that is
also involved in DNA synthesis during replication [51]. In
addition, because this protein is nearly identical to the
promoter binding protein of the angiotensinogen gene [51],
its increased expression may be associated with increased
renal levels of angiotensin II, a hormone to which several
direct and indirect fibrogenic activities have been ascribed
[52].
As described earlier by our group [23], CsA treatment
increased PAI-1 lysosomal staining in atrophic tubules
located within subcapsular cortical foci, but due to the use
of different fixation methods for PAI-1 immunostaining
and TIMP-1 ISH, we were unable to determine whether the
interstitial TIMP-1 transcribing cells were localized around
PAI-1 containing atrophic tubules.
The ability of macrophages to produce fibrosis-inducing
cytokines appears to be critical in the progression of
tubulointerstitial fibrosis [53–55]. Macrophage depleting
protocols ameliorate renal function and reduce the severity
of interstitial fibrosis in several models of chronic tubulo-
interstitial damage [22, 55]. In kidneys from vehicle-treated
rats a small population of macrophages resides in the
interstitium. Three weeks of CsA treatment significantly
increases the number of macrophages in fibrotic areas and
macrophage recruitment and/or proliferation appeared to
be sensitive to CsA dosage, as the highest numbers of
macrophages were encountered in kidneys of rats receiving
the highest CsA dose. Monocytes/macrophages are re-
cruited into the renal interstitium in response to several
chemoattractants released by tubular cells in response to
damage elicited by CsA [54]. The CsA-induced increase of
oxidized lipoproteins [56] may also contribute to the re-
cruitment of monocytes into kidneys after CsA-treatment,
as oxidized lipoproteins exert chemoattractive activities on
monocytes [57]. In addition to recruitment from extrarenal
sources, possibly TIMP-1 mediated mitogenic stimuli may
lead to interstitial hypercellularity due to macrophage
proliferation, as this is partly the case in our model of
chronic CsA nephropathy where a small subpopulation of
the resident macrophages stain positively for PCNA and
since both PCNA positivity and TIMP-1 mRNA expression
were highest in the group receiving the highest CsA dose.
The transformation of fibroblasts into myofibroblasts
plays a role in tissue repair and renal fibrosis [58]. In
control kidneys a-SMA was mainly expressed by vascular
smooth cells in cortical arteries and arterioles and a-SMA
was absent from the interstitial space except from some
rare interstitial a-SMA positive cells lining Bowman’s
capsule. The focal increase of interstitial a-SMA expression
after CsA administration may serve as a predictor of
progressive renal dysfunction. In rodent models of progres-
sive renal injury such as urinary outlet obstruction and
chronic mesangial proliferative glomerulonephritis, pheno-
type switching of renal interstitial cells is associated with
increased matrix deposition. One of the early pathological
events that occur after 5/6 nephrectomy in the rat, is the
transformation of renal cells, in which they acquire myofi-
broblast characteristics [54]. The origin of these myofibro-
blasts is still controversial; these cells may stem from
perivascular cells, vascular smooth muscle cells, resident
interstitial fibroblasts [59] or even from tubular cells, since
Okada and co-workers found fibroblastic specific protein
(FSP1)-positive tubular cells in an inflamed kidney, sug-
gesting a phenotyic conversion of tubular cells into fibro-
blasts. The very modest interstitial expression of a-SMA
after three weeks of CsA treatment indicates that the
process of myofibroblast transformation and migration has
just begun and may continue to increase as interstitial
fibrosis progresses.
The results of our study suggest that the locally increased
expression of TIMP-1 in the kidney, rather than a decrease
of protease expression, contributes to the development of
CsA-induced focal interstitial fibrosis in the rat. The re-
cruitment of macrophages appears to be critical in the
progression of CsA-induced tubulointerstitial fibrosis and is
affected by CsA dosage since the highest number of
macrophages were counted in kidneys of rats treated with
20 mg CsA/kg body wt. The increased TIMP-1 message
levels in the fibrotic cortex may be originating from mac-
rophages recruited into injured areas and/or from resident
renal cells that acquired fibrogenic mesenchymal cell char-
acteristics, as the number of a-SMA expressing cells in-
creased after three weeks of CsA treatment.
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APPENDIX
Abbreviations used in this article are: AEC, 3-amino-9-
ethylcarbazole; a-SMA, a-smooth muscle actin; BCIP,
5-bromo-4-chloro-3-indolyl phosphate; CsA, cyclosporine
A; DAB, 3,39-diaminobenzidene; DEPC, diethylpyrocar-
bonate; FSP1, fibroblastic specific protein; GAPDH, glyc-
eraldehyde-3-phosphate dehydrogenase; ISH, in situ hy-
bridization; LPS, lipopolysaccharide; MMP, matrix
metalloproteinase; NBT, nitroblue tetrazolium salt; NTE,
Tris-EDTA buffer; PA, plasminogen activating; PAI-1,
plasminogen activator inhibitor type-1; PAN, puromycin
aminonucleoside nephrosis; PAS, periodic acid Schiff;
PCNA, proliferating cell nuclear antigen; SSC, standard
saline citrate; TGF-b1, transforming growth factor-b1;
TIMP-1, tissue inhibitor of matrix metalloproteinase-1;
TSB, Tris saline buffer.
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